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The Wilms' tumor 1 geneWT1 encodes a zinc transcription factor involved in a variety of cancer-related processes. In
this study, we sought to investigate the effects of WT1 splice variants on tumorigenic activity and survival in an in vivo
ovarian cancer model. To this end, we established stable ovarian cancer cell lines transduced with lentiviral constructs
containing each of the four WT1 splice variants (−17AA/−KTS, +17AA/−KTS, −17AA/+KTS, and +17AA/+KTS).
In mice inoculated intraperitoneally with SKOV3ip1 cells expressingWT1−17AA/−KTS, disseminated tumor weights
andproductionof asciteswere significantly increased comparedwith those inmice inoculatedwith cells expressing the
control vector. The overall survival in mice inoulatedwithWT1−17AA/−KTS-expressing cells was significantly shorter
than that in mice inoculated with control cells (P = .0115). Immunoblot analysis revealed that WT1 −17AA/−KTS
significantly increased the expression of vascular endothelial growth factor (VEGF) compared with the control. Greater
numbers of CD31-immunopositive vessels were observed in tumors from mice injected with cells expressing
WT1 −17AA/−KTS than in tumors from control mice. Finally, WT1 −17AA/−KTS significantly increased tumor
microvessel density compared with that in the control (P b .05). Treatment with anti-VEGF antibody (bevacizumab)
inhibited tumor growth, dissemination, and ascites production inmice injectedwith cells expressingWT1−17AA/−KTS.
The overexpression of WT1−17AA/−KTS induced a more aggressive phenotype in ovarian cancer cells through VEGF
up-regulation in an in vivo ovarian cancer model. Our findings indicated that WT1−17AA/−KTS enhanced tumorigenic
activity and could decreased patient survival through up-regulation of VEGF expression in ovarian cancers.
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Wilms' tumor gene WT1 is located on chromosome 11q13 and it
encodes a zinc finger transcription factor [1]. The WT1 protein
activates or represses the transcription of many target genes involved
in the cell cycle, proliferation, differentiation, and apoptosis [2–4].
WT1 was initially identified as a tumor suppressor gene due to its
inactivation in Wilms' tumor (nephroblastoma), the most common
pediatric kidney tumor [5]. However, recent findings have shown
that WT1 acts as an oncogene in some cancers, including ovarian
cancer [6–11]. Previous studies have demonstrated that high
expression levels of WT1 correlate with poor prognosis in leukemia[12] and breast cancer [13] and with more advanced tumor stages in
testicular germ cell tumors [14] and head and neck squamous cell
carcinoma [15].
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carcinoma, a more aggressive subtype [16]. Moreover, our unpub-
lished data demonstrated that high levels of WT1 expression yielded
tumors with more aggressive International Federation of Gynecology
and Obstetrics (FIGO) stages, lymph node metastasis status,
omentum metastasis status, and ascites production in ovarian cancers.
Several studies examining the correlation between WT1 expression
and survival have found WT1 to be indicative of unfavorable
prognoses in patients with ovarian cancers [16,17]; however, other
studies have reported that WT1 expression may be of limited
prognostic value in ovarian cancers in the clinical setting [18,19].
This raises important questions about the lack of a significant
correlation between WT1 expression levels and survival, despite the
observation that WT1 acts as an oncogene and is highly expressed in
more aggressive histological subtypes.
WT1 is spliced alternatively at two sites: exon 5 with 17AA and the
KTS site, which exists between exons 9 and 10. Splicing at these sites
yields four variants (−17AA/−KTS, +17AA/−KTS, −17AA/+KTS,
and +17AA/+KTS) [20–23]. Several studies have reported that the four
WT1 splice variants have different functions in various cancers.
WT1 +17AA/−KTS induces programmed cell death through
transcriptional repression of the EGFR gene in osteosarcoma cells
[24].WT1 +17AA/+KTS can cause amorphological transition from an
epithelial phenotype to a more mesenchymal phenotype in mammary
epithelial cells [25]. In ovarian cancers, WT1 −17AA/−KTS induces
morphological changes and promotes cell migration and invasion in
vitro [20]. Moreover, a recent study investigated the expression ofWT1
splice variants using real-time PCR and reported that the ratio of WT1
variants, particularly +17AA variants, is probably crucial for the process
of malignant transformation in acutemyeloid leukemia [26]. Therefore,
it is possible that the ratio of expressedWT1 splice variants is associated
with the lack of a significant correlation between total WT1 expression
and survival in patients with ovarian cancers.
Therefore, in this study, we examined four WT1 splice variants
having distinct functions in ovarian tumorigenicity using stable
ovarian cancer cell lines overexpressing each splice variants. We also
examined the effects of WT1 variants on tumor growth, dissemina-
tion, and ascites production using an ovarian cancer mouse model.
Materials and Methods
Cell Cultures
The SKOV3ip1 cell line was generated from ascites developed in
nu/nu mice by administering an intraperitoneal injection of human
ovarian carcinoma cell line SKOV3 [27]. The SKOV3ip1 cell line
was cultured at 37°C in M199:105 medium with 10% fetal bovine
serum (FBS) and 1% penicillin-streptomycin in a humidified
atmosphere of 95% air and 5% CO2.
WT1 Plasmids
Four pcDNA 3.1(+) vectors (Invitrogen, Carlsbad, CA, USA) were
engineered to contain one of the four human WT1 splice variants
(−17AA/−KTS, +17AA/−KTS, −17AA/+KTS, or +17AA/+KTS)
[20]. The sequences of each of these four WT1 variants were
amplified from the corresponding vector by PCR using primers
containing BglII and NotI restriction sites (sense primer sequence, 5′-
AGA TCT GAC TTC CTC TTG CTG CA-3′; antisense primer
sequence, 5′-GCG GCC GCT TGA AAG CAG TTC ACA CAC T-
3′), digested, and ligated into the lentiviral vector plasmid, pHR-SIN-
CSGW dlNotI [28] (a gift from Y. Ikeda, Mayo Clinic, Rochester,MN, USA). We introduced each of the four WT1 splice variants in
place of eGFP using the BamHI and NotI sites in pHR-SIN-CSGW
dlNotI. The resulting plasmids were designated as WT1 −17AA/−
KTS−, +17AA/−KTS−, −17AA/+KTS−, or +17AA/+KTS-pHR-
SIN-CSGW dlNotI. We deleted the eGFP sequence in pHR-SIN-
CSGW dlNotI and used this modified vector as a control vector.
Preparation of infectious particles was performed according to
established protocols [29].
Intraperitoneal Xenograft Model and Treatment in Vivo
All of the procedures involving animals in this study were approved
by the animal care committee of Yamagata University in accordance
with institutional and Japanese government guidelines for animal
experiments. WT1 splice variants (−17AA/−KTS, +17AA/−KTS,
−17AA/+KTS, and +17AA/+KTS) or control lentivirus vectors were
co-transfected with packaging plasmids (pVSV-G and pGag/pol) into
293 T cells to generate lentiviral particles. These particles were then
used to transduce SKOV3ip1 cells, and cells stably expressing the vectors
were selected with 1 μg/mL puromycin. SKOV3ip1 cells (2 × 106)
expressing WT1 variants (−17AA/−KTS [n = 13], +17AA/−KTS
[n = 13], −17AA/+KTS [n = 8], or +17AA/+KTS [n = 10]) or
control vector (n = 8) were suspended in 250 μL PBS and inoculated
by intraperitoneal injection (i.p.) into 5- to 7-week-old female BALB/
CA nu/nu mice. Abdominal circumference and body weight were
measured twice weekly. Mice injected with WT1 −17AA/−KTS-
expressing cells were euthanized with CO2 after 36 days and mice
injected with cells expressing control vector or the other variants were
euthanized after 40 days to assess tumorigenecity by measuring volume
of ascites, extent of dissemination, and weight of tumors. We used data
from mice that were euthanized precisely after 36 or 40 days.
In a second experiment, 2 × 106 SKOV3ip1 cells expressing
the control vector or each WT1 variant were injected i.p. into 5- to
7-week-old female BALB/CA nu/nu mice (n = 30, with 6 mice per
group of cells), and survival was evaluated from the first day of
inoculation until death.
In a third experiment, SKOV3ip1 cells (2 × 106) expressing WT1
−17AA/−KTS were implanted by i.p. into 5- to 7-week-old nu/nu
nude mice (n = 10). After two week after inoculation, one group of
mice (n = 5) was treated i.p with PBS twice weekly for 3 weeks. A
second group ofmice (n = 5)was treated ipwith bevacizumab (5 mg/kg)
twice weekly for 3 weeks. Bevacizumab was kindly provided by Chugai
Pharmaceutical Co., Ltd. (Tokyo, Japan). Bevacizumab were diluted in
200 μl of PBS. Abdominal circumference and body weight were
measured once a week. At 3 weeks after initiating treatment, mice were
euthanized with CO2 to assess antitumor efficacy of bevacizumab by
measuring volume of ascites and weight of tumors.
Reverse Transcription (RT)-PCR
Briefly, tumors were homogenized in RLT buffer. Total RNA was
isolated and purified with an RNeasy− Mini kit (Qiagen, Valencia,
CA, USA). cDNA was generated form 0.4 μg RNA using a
QuantiTect Reverse Transcription kit (Invitrogen).
cDNA (1.0 μL) was used for PCR amplification in total volume of
25 μL. The PCR primer sets used for identifying WT1 splice variants
[9] were as follows: forward primer (F2), 5′-GAC CTG GAA TCA
GAT GAA CTT AG-3′; reverse primer (R2), 5′-GAG AAC TTT
CGC TGA CAA GTT-3′; forward primer (F3), 5′-GTG TGA AAC
CATTCCAGTGTA-3′; and reverse primer (R3), 5′-TCCTGACAA
CTT GGC CAC CG-3′. WT1 forward (F2) and reverse primers (R2)
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primers (R3) spanned the KTS coding sequence. The thermal cycle
profile used for amplification of WT1 splice variants was 35 cycles of
denaturation at 94 °C for 30 s, annealing at 58 °C for 30 s, and
extension at 72 °C for 60 s. PCR products were electrophoresed on 2%
agarose gels containing ethidium bromide and photographed.
Western Blotting
Tumors were homogenized in 400 μL lysis buffer (20 mmol/L
Tris–HCl [pH 7.5], 150 mmol/L NaCl, 1 nmol/L Na2EDTA,Figure 1. Confirmation of each WT1 splice variant and the appearanc
(A) SKOV3ip1 cells expressing control vector, WT1 −17AA/−KTS,
subjected to western blotting using anti-WT1 and anti–β-actin anti
experiment. (C) Body weight gain was calculated by subtracting the bo
from each of the five groups. (D) Abdominal circumference gain was c
the experiment from that at the start in mice from each of the five grou
shown as means ± SEs. Significant differences are indicated by ast1 mmol/L EGTA, 1% Triton, 2.5 mmol/L sodium PPi, 1 mmol/L
β-glycerophosphate, 1 mmol/L phenylmethylsulfonyl fluoride).
Homogenates were centrifuged at 10,000 rpm at 4 °C for 10 min,
and the protein concentrations of the supernatants were determined
using a protein assay reagent (Bio-Rad Laboratories, Hercules, CA).
Thirty micrograms of protein isolated from tumors expressing each
WT1 splice variant was separated by SDS-PAGE and transferred to
nitrocellulose membranes. Blocking was carried out in 5% skim milk.
Protein spots were immunoblotted with anti-WT1 (c-19, Santa Cruz
Biotechnology, Santa Cruz, CA, USA), anti–β-actin (AC74, Sigma),e, weight gain, abdominal circumference gain, and ascites of mice.
+17AA/−KTS, −17AA/+KTS, or +17AA/+KTS were lysed and
bodies. (B) Representative images of the mice at the end of the
dy weight at the end of the experiment from that at the start in mice
alculated by subtracting the abdominal circumference at the end of
ps. (E) The volume of ascites was measured at autopsy. Values are
erisks. **P b .01; *P b .05.
Translational Oncology Vol. 7, No. 5, 2014 WT1 -17AA/-KTS increase tumorigenicity in ovarian cancer Yamanouchi et al. 583anti-VEGF (A-20, Santa Cruz Biotechnology), and anti-CD31/
PECAM-1 antibodies (M-20, Santa Cruz Biotechnology).
Immunohistochemistry
Tumor tissues that had disseminated into the abdomen were fixed in
4% paraformaldehyde and embedded in paraffin. Paraffin-embedded
tissue sections were incubated with anti-CD31/PECAM-1 antibodies
(Santa Cruz Biotechnology; 1:50 dilution) followed by peroxidase-
conjugated secondary antibodies. The tissue sectionswere viewed at 100×
magnification, and images were captured. Four fields per section wereA
B
C
Figure 2. The effects of eachWT1 splice variant on tumorigenesis in v
The yellow arrowhead indicates the intra-abdominal dissemination
weight was measured. (C) The disseminated tumor was fixed with 4%
tissue sections were stained with hematoxylin and eosin. The
cystoadenocarcinoma. Values of disseminated tumor weights are s
asterisks. ***P b .05, **P b .01; *P b .05.randomly analyzed. The microvessel density (MVD, number/mm2) in
each field was calculated (number of CD31-positive objects/
0.644 mm2). Mean values of MVD in each group were calculated
from the intra-abdominally disseminated tumors developed in mice
injected with cells expressing control vector or WT1 −17AA/−KTS.
Statistics
Statistical analysis was performed using one-way ANOVA in
Graph-Pad Prism 5 software, and P values of less than .05 indicated
significant differences. Data are expressed as the mean ± SE.ivo. (A) Representative image of mouse appearance on laparotomy.
of the tumor. (B) The disseminated tumor was removed, and the
paraformaldehyde and embedded in paraffin. Paraffin-embedded
disseminated tumor showed histological findings of serous
hown as the mean ± SE. Significant differences are indicated by
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Effects of WT1 Splice Variants on Tumorigenicity in
Ovarian Cancer
SKOV3ip1 cells were stably transduced with lentiviral constructs
containing control vector, WT1 −17AA/−KTS, WT1 +17AA/−KTS,
WT1 −17AA/+KTS, or WT1 +17AA/+KTS, and immunoblot
analysis showed high levels of WT1 expression in SKOV3ip1 cells
transduced with each WT1 variant (Figure 1A). To test whether
SKOV3ip1 cells transduced with each WT1 variant or control vector
could be tumorigenic in vivo and to observe the pattern of tumor
growth, we implanted these cells into nude mice (n = 3 for each of the
five different cell type). SKOV3ip1 cells expressing WT1 −17AA/−KTS
rapidly produced tumors (3/3), and mice injected with the cells were
usually dead within 40 days, while mice injected with SKOV3ip1
cells expressing control vector (3/3), WT1 +17AA/−KTS (3/3), WT1
−17AA/+KTS (3/3), or WT1 +17AA/+KTS (3/3) developed only
small tumors, even after 40 days. Based on these preliminary data, we
euthanized mice injected with WT1 −17AA/−KTS-expressing cells
on day 36 and mice injected with cells expressing control vector or the
other variants on day 40.
The appearances of the mice are shown in Figure 1B. Mice injected
with cells expressing −17AA/−KTS showed a significant increase in
body weight gain compared to mice injected with cells expressingFigure 3. Confirmation of WT1 expression in tumors. (A) Intra-abdom
cells expressing the control vector, −17AA/−KTS, +17AA/−KTS, −
by immunoblot analysis with anti-WT1 antibodies, using β-actin as a lo
WT1 −17AA/−KTS were used as positive controls (PC) and those
analysis using F2 and R2 primers showed two bands; the upper band
absence of 17AA. PCR analysis using F3 and R3 primers showed tw
lower band indicated the absence of KTS. cDNA form OV202 cells,
distilled water was used as a negative control (NC).control vector, +17AA/−KTS, or −17AA/+KTS (Figure 1C).However,
there were no significant differences in abdominal circumference gains
among the five groups ofmice (Figure 1D). Interestingly, overexpression
of the −17AA/−KTS splice variant resulted in a significant increase in
the volume of ascites, compared with that in mice infected with cells
expressing the control vector or other WT1 variants (Figure 1E).
The extent of intra-abdominal dissemination is visually shown in
Figure 2A. Massive intra-abdominal dissemination was detected in
mice injected with cells expressing the WT1 −17AA/−KTS variant.
Mice injected with cells expressing the control vector, WT1 +17AA/
−KTS, WT1 −17AA/+KTS, or WT1 +17AA/+KTS showed a little
intra-abdominal dissemination. Histological analysis of intra-abdom-
inal lesions developed in mice injected with cells expressing the
control vector or each variant confirmed the findings of serous
adenocarcinoma (Figure 2B), which was consistent with SKOV3ip1
cells, as described previously [30]. There was no difference in
histological findings in cells expressing each of the four WT1 variants
(Figure 2B). Tumors that had disseminated within the abdomen were
measured by resected tumor weight (Figure 2C). Overexpression of
−17AA/−KTS resulted in a significant increase in the disseminated
tumor weight, as compared with that in tumors expressing the
control vector or +17AA/+KTS variant. There were no significant
differences in disseminated tumor weights in mice injected with cells
expressing the control vector or other variants.inally disseminated tumors were harvested from mice injected with
17AA/+KTS, or +17AA/+KTS, and WT1 expression was assessed
ading control. Whole cell lysates of SKOV3ip1 cells transducedwith
of SKOV3 ip1 cells were used as negative controls (NC). (B) PCR
indicated the presence of 17AA, while the lower band indicated the
o bands; the upper band indicated the presence of KTS, while the
which expressed WT1, was used as a positive control (PC), while
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Immunoblot analysis showed that WT1 was abundantly expressed
in tumors obtained from mice inoculated with cells expressing the
four variants (Figure 3A). Absence of WT1 expression was confirmed
in tumors from mice inoculated with cells expressing the control
vector. Additionally, PCR analysis of RNA extracted from the tumors
confirmed the expression of each WT1 variant, including the specific
17AA/KTS insertion/deletion, and the absence of WT1 from the
control (Figure 3B).
The Effects of WT1 Splice Variants on Survival
We also examined the effects of the WT1 variant on the survival of
mice with ovarian cancer. The survivals curve of all mice injected with
cells expressing the control vector or each WT1 variant are shown in
Supplementary Data 1. The median survival times of mice inoculated
with cells expressing control vector, WT1 −17AA/−KTS, +17AA/−KTS,
−17AA/+KTS, and +17AA/+KTS were 54.5 (range, 52-107), 45 (range,
43-53), 56.5 (range, 44-177), 78 (range, 60-94), and 60.5 (range, 54-178)
days, respectively. Moreover, WT1 −17AA/−KTS alone significantly
shortened survival compared with the control (P = .0115; Figure 4).
WT1 −17AA/−KTS Increased the Expression of VEGF and
Promoted Angiogenesis In Vivo
Our data showed that overexpression of WT1 −17AA/−KTS
enhanced tumorigenic activity and resulted in a poor outcome
in our ovarian cancer model. However, it was unclear how WT1
−17AA/−KTS contributed to tumorigenicity and influenced
survival in ovarian cancers. Previous study have shown that WT1
splice variants regulate various genes, such as CCND2, PCNA,
IGFBP5, EGR-1, and VEGF [31,32]. Therefore, we next examined
the mRNA expression levels of these genes in tumors from mice
inoculated with cells expressing the control vector orWT1 −17AA/−
KTS by RT-PCR.We confirmed thatWT1 −17AA/−KTS increased
the mRNA expression of VEGF compared with the control vector;
however, WT1 −17AA/−KTS did not affect the expression of
other genes, such as CCND2, PCNA, IGFBP5, or EGR-1
(Supplementary Data 2). Moreover, immunoblot analysis revealed
that WT1 −17AA/−KTS significantly increased the expression of
VEGF at the protein level, as compared with the control (Figure 5A).
We next examined whether WT1 −17AA/−KTS promoted
angiogenesis in vivo. As shown in Figure 5B, larger numbers ofFigure 4. The effects of WT1 −17AA/−KTS on overall survival in
vivo. Mice were inoculated with cells expressing control vector or
WT1 −17AA/−KTS. The mice were observed until death. Overall
survival was estimated using the Kaplan–Meier method.CD31-immunopositive vessels were observed in tumors from mice
injected with cells expressing WT1 −17AA/−KTS than in tumors
from control mice. WT1 −17AA/−KTS significantly increased
tumor MVD compared with the control (P b .05; Figure 5C).
The Effects of Anti-VEGF Antibody on WT1 −17AA/−KTS-
Induced Tumor Growth and Ascites Production.
To investigate whether anti-VEGF antibody inhibited tumor growth
and ascites formation enhanced by WT1 −17AA/−KTS overexpres-
sion, we administered bevacizumab to athymic mice inoculated with
SKOV3ip1 cells (2 × 106) expressingWT1 −17AA/−KTS.Twoweeks
after inoculation, the mice were randomized into two groups; the first
group received PBS (n = 5) twice weekly for 3 weeks, while the second
group received 5 mg/kg bevacizumab (n = 5) twice weekly. One of the
mice treated with PBS was dead before the end of the experiment. The
appearances of the mice are shown in Figure 6A. Body weight and
abdominal circumference were measured at the end of the experiment.
Mice treated with bevacizumab showed a significant decrease in body
weight and abdominal circumference compared to mice treated with
PBS (Figure 6, B and C). Treatment with bevacizumab completely
inhibited ascites production (Figure 6D). Moreover, mice treated with
bevacizumab showed a significant decrease in the disseminated tumor
weight, as compared tomice treatedwith PBS (Figure 6E). These results
suggested that inhibition of VEGF attenuated the enhancing effect of
WT1 −17AA/−KTS on tumorigenic activity and ascites formation.
Discussion
This is the first report to examine the effects of WT1 splice variants
on tumorigenic activity using an ovarian cancer mouse model. We
established stable SKOV3ip1 cell lines overexpressing each of the
four WT1 variants (−17AA/−KTS, +17AA/−KTS, −17AA/+KTS,
or +17AA/+KTS) using lentiviral constructs and found that
WT1 −17AA/−KTS increased tumor growth, dissemination, and
ascite production and shortened survival. We also found that
WT1 −17AA/−KTS induced the expression of VEGF and that
anti-VEGF antibody inhibited the tumor growth and ascites
formation enhanced by WT1 −17AA/−KTS overexpression. Collec-
tively, these data indicated that WT1 −17AA/−KTS enhanced
tumorigenicity through up-regulation of VEGF and induced cellular
transform into a more aggressive phenotype in ovarian cancers.
The WT1 gene was initially identified as a tumor suppressor gene
due to its inactivation in Wilms' tumor (nephroblastoma), the most
common pediatric kidney tumor [33]. However, recent findings have
shown that WT1 acts as an oncogene in some tumors, including
ovarian cancers [6–11]. Several studies have reported that the four
WT1 splice variants have different functions in various cancers. For
example, WT1 −17AA/−KTS has been shown to induce morpho-
logical changes and promote cell migration and invasion in ovarian
cancer (TYK) cells [20]. In mammary cells, WT1 +17AA/+KTS
causes a morphological transition from an epithelial to a more
mesenchymal phenotype [25]. Our in vivo data showed no difference
in histological findings in cells expressing each of the four WT1
variants (Figure 2B). We also examined the function of WT1 splice
variants on cell invasion in vitro using SKOV3ip1 cells transduced
with lentiviral constructs containing an empty (control) vector or each
WT1 variant. All isoforms enhanced cell invasion compared with the
control, and there was no significant difference among each of the
four WT1 splice variants (data not shown). Our in vivo data showed
that WT1 −17AA/−KTS increased tumor growth, dissemination,
and ascite production in ovarian cancers. This result was consistent
Figure 5. The effects of the WT1−17AA/−KTS splice variant on the expression of VEGF protein and angiogenesis. (A) Intra-abdominally
disseminated tumors were harvested from mice injected with cells expressing control vector or −17AA/−KTS and assessed for VEGF
expression by immunoblot analysis with anti-VEGF and anti–β-actin antibodies (bottom panel). Relative densitometric units of VEGF bands
are shown,with the density of control bands set arbitrarily to 1.0 (top panel). The values shown represent themean ± SE fromat least three
separate experiments. (B) Tumor tissues that had disseminated in the abdomen were fixed in 4% paraformaldehyde and embedded in
paraffin. Paraffin-embedded tissue sections were incubated with anti–CD31/PECAM-1 antibodies and imaged at magnification of 200×
(top panel) and 400× (bottom panel). (C) The number of CD31-immunopositive microvessels was measured in tissue sections harvested
from mice injected with cells expressing control vector or WT1 −17AA/−KTS. The yellow arrow-head indicates CD31-immunopositive
microvessels. The values shown represent the mean ± SE. Significant differences are indicated by asterisks. *P b .05.
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increases tumor growth through EGR-1 up-regulation in adenovirus-
transformed baby rat kidney (AdBRK) cells in vivo [32]. In contrast,
several studies have shown that WT1 variants act as tumor
suppressors. WT1 −17AA/–KTS and +17AA/−KTS suppress the
invasive ability of lung cancer cells by regulating p21 expression [34].
Moreover,WT1 −17AA/−KTS suppresses proliferation and induces a
G2-phase cell cycle arrest in mammary epithelial cells [25]. Thus, each
of the four WT1 variants has distinct functions depending on the
cancer type. Our data suggested that WT1 −17AA/−KTS increased
tumorigenic activity and acted as an oncogene in ovarian cancers.
Several reports have demonstrated that high expression of WT1
correlates with aggressiveness and poor outcomes in various cancers[12–15]. Additionally, whileWT1 is indicative of unfavorable prognoses
in patients with ovarian cancers [16],WT1 expressionmay be of limited
prognostic value in ovarian cancers in the clinical setting [18,35]. This
may be attributed to inconsistent results in analysis of the association of
prognosis with the ratio of WT1 variant expression in patients with
ovarian cancers. Our results showed that WT1 −17AA/−KTS
shortened survival in mice in our ovarian cancer model (Figure 4).
These findings indicated that the presence of WT1 −17AA/−KTS
could affect the survival of mice with ovarian cancer. Therefore, the
expression of WT1 −17AA/−KTS may be more important in the
prognoses of patients with ovarian cancers than that of total WT1.
In addition, our data showed that WT1 −17AA/−KTS increased
the expression of VEGF protein and promoted angiogenesis
Figure 6. Theeffect of bevacizumabon tumor growth in vivo. Athymicnudemice inoculatedwith SKOV3ip1cells expressingWT1−17AA/−KTS
(n = 10)were randomly placed into twogroups. One group ofmice (n = 5)was treatedwith PBS and two group ofmice (n = 5)were treated
with bevacizumab twiceweekly for 3 weeks, asdescribed inMaterials andMethods. (A) The representative appearanceof themice at theend
of the experiment. (B) Body weight gain was calculated by subtracting the body weight at the end of the experiment from that at the start in
mice from the two groups. (C) Abdominal circumference gain was calculated by subtracting the abdominal circumference at the end of the
experiment from that at the start inmice from twogroups. (D) The volumeof asciteswasmeasured at autopsy. (E) Disseminated tumorswere
removed, and tumor weights were measured. The values shown represent the means ± SEs. Significant differences are indicated by
asterisks. *P b .05.
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bevacizumab attenuated the enhancing effect of WT1 −17AA/−KTS
on tumorigenic activity. VEGF regulates cell proliferation and
angiogenesis through the activation of PI3K/Akt and MEK/ERK
signaling [36], and is associated with poor prognoses in many human
cancers, including ovarian cancers [37–40]. Moreover, VEGF-targeting
therapy using bevacizumab prolongs the median progression-free
survival [41,42] and has an important role in current therapies for
patients with advanced ovarian cancer. Our data indicated that
overexpression of WT1 −17AA/−KTS could increase tumorigenic
activity and shorten survival through up-regulation of VEGF expression
in ovarian cancers. Therefore, WT1 −17AA/−KTS expression may be
biomarker of VEGF-targeting therapy, including bevacizumab, in
patients with ovarian cancer.In summary, we concluded that the overexpression of WT1
−17AA/−KTS could enhanced tumorigenicity and could decrease
survival through up-regulation of VEGF in an in vivo ovarian cancer
model. WT1 −17AA/−KTS expression may be correlated with the
poor survival of patients with ovarian cancer and may be a promising
therapeutic target for ovarian cancer. Furthermore, since the present
study was performed using a mouse ovarian cancer model without a
true immune system, additional work is required to identify the role
of WT1 splice variants in the patients with ovarian cancer.
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